Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD
Restricted accessResearch articleFirst published online November, 2018
Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD
Paclitaxel is widely used as a radiosensitizer for various tumors, including esophageal cancer, but its therapeutic effect remains to be improved. In this study, we constructed a novel nano-radiosensitizer, anti-EGFR-iRGD-conjugated (iE)-PRNPs, by conjugating the recombinant protein anti-epidermal growth factor receptor (EGFR)-internalizing arginine-glycine-aspartic (iRGD) to the surface of paclitaxel-loaded red blood cell membrane nanoparticles (PRNPs). The iE-PRNPs were confirmed to possess tumor-targeting, high penetrability, and sustained release properties that free paclitaxel does not possess. Compared with that of paclitaxel, the sensitizer enhancement ratio of iE-PRNPs was significantly increased (1.32-fold and 1.25-fold) in esophageal cancer cells with high and low expression levels of EGFR, respectively. Additionally, compared with that of unmodified PRNPs, the sensitizer enhancement ratio of iE-PRNPs in EGFR-overexpressing esophageal cancer cells was significantly increased (1.27-fold), while that of PRNPs in esophageal cancer cells with a low EGFR expression level increased slightly (1.06-fold). The improved radiosensitization effect was associated with enhanced G2/M arrest, increased reactive oxygen species, and more effective induction of DNA double-strand breaks. In summary, iE-PRNPs appear to be a novel type of radiosensitizer with the potential to overcome the bottleneck of esophageal cancer radiotherapeutic efficacy.
TrachoothamDAlexandreJHuangP.Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nat Rev Drug Discov2009;
8: 579–591.
4.
TurinettoVGiachinoC.Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions. Nucleic Acids Res2015;
43: 2489–2498.
5.
SakAStuschkeM.Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol2010;
20: 223–231.
6.
ChenWZhengRBaadePDet al.
Cancer statistics in China, 2015. CA Cancer J Clin2016;
66: 115–132.
7.
ShapiroJvan LanschotJJBHulshofMet al.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol2015;
16: 1090–1098.
8.
van HagenPHulshofMCvan LanschotJJet al.
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;
366: 2074–2084.
9.
van HagenPWijnhovenBPNafteuxPet al.
Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg2013;
100: 267–273.
10.
CooperJSGuoMDHerskovicAet al.
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;
281: 1623–1627.
11.
MinskyBDPajakTFGinsbergRJet al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167–1174.
12.
PiessenGMessagerMMirabelXet al.
Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg2013;
258: 793–799; discussion 799–800.
13.
LiuQLiRTQianHQet al.
Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials2013;
34: 7191–7203.
14.
WangKLWuTTChoiISet al.
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer2007;
109: 658–667.
15.
AichlerMMotschmannMJuttingUet al.
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget2014;
5: 6620–6632.
16.
HanawaMSuzukiSDobashiYet al.
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer2006;
118: 1173–1180.
17.
JiangDLiXWangHet al.
The prognostic value of EGFR overexpression and amplification in esophageal squamous cell carcinoma. BMC Cancer2015;
15: 377.
18.
LiangJ, EM, WuGet al.
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. Onco Targets Ther2013;
6: 1589–1596.
19.
MengXWangJSunXet al.
Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail. Radiother Oncol2013;
109: 275–280.
20.
MagnaniMRossiL.Approaches to erythrocyte-mediated drug delivery. Expert Opin Drug Deliv2014;
11: 677–687.
21.
GaoWHuCMFangRHet al.
Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater2013;
25: 3549–3553.
ShaHLiRBianXet al.
A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo. Eur J Pharm Sci2015;
77: 60–72.
24.
ShaHZouZXinKet al.
Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release2015;
200: 188–200.
25.
LordickFMarietteCHaustermansKet al.
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2016;
27: v50–v57.
26.
JiangXWangKZhouZet al.
Erythrocyte membrane nanoparticles improve the intestinal absorption of paclitaxel. Biochem Biophys Res Commun2017;
488: 322–328.
27.
BradleyJPaulusRKomakiRet al.
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol2015;
16: 187–199.
28.
WernerMECummingsNDSethiMet al.
Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys2013;
86: 463–468.
29.
HanHDMangalaLSLeeJWet al.
Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res2010;
16: 3910–3922.
30.
HaspelNZanuyDNussinovRet al.
Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach. Biochemistry2011;
50: 1755–1762.
31.
TeesaluTSugaharaKNKotamrajuVRet al.
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A2009;
106: 16157–16162.
32.
SugaharaKNTeesaluTKarmaliPPet al.
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell2009;
16: 510–520.
33.
NakamuraHFangJMaedaH.Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv2015;
12: 53–64.
34.
MinchintonAITannockIF.Drug penetration in solid tumours. Nat Rev Cancer2006;
6: 583–592.
35.
Abedi-ArdekaniBDarNAMirMMet al.
Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia. BMC Cancer2012;
12: 602.
36.
ZhangWZhuHLiuXet al.
Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. Ann Thorac Surg2014;
98: 513–519.
37.
CuiFBLiRTLiuQet al.
Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer. Cancer Lett2014;
346: 53–62.
38.
NehateCJainSSanejaAet al.
Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv2014;
11: 666–686.
39.
LuJChuanXZhangHet al.
Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int J Pharm2014;
471: 525–535.
40.
ShinHCAlaniAWRaoDAet al.
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release2009;
140: 294–300.
41.
GaucherGDufresneMHSantVPet al.
Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release2005;
109: 169–188.
42.
HuQGaoXGuGet al.
Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials2013;
34: 5640–5650.
43.
DanhierFVromanBLecouturierNet al.
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release2009;
140: 166–173.
44.
BaleASBaroneSJrScottCSet al.
A review of potential neurotoxic mechanisms among three chlorinated organic solvents. Toxicol Appl Pharmacol2011;
255: 113–126.
45.
SunYSuJLiuGet al.
Advances of blood cell-based drug delivery systems. Eur J Pharm Sci2017;
96: 115–128.
46.
TzounakasVLKaradimasDGPapassideriISet al.
Erythrocyte-based drug delivery in transfusion medicine: wandering questions seeking answers. Transfus Apher Sci2017;
56: 626–634.
